// App-Quantinova.ai

e20011 : Time to deterioration (TTD) in health-related quality of life (HRQoL) with carfilzomib plus dexamethasone (Kd56) versus bortezomib plus dexamethasone (Vd) in the ENDEAVOR trial.

Researchers

Presenter

  • Katja Weisel

Principal Investigators

  • Heinz Ludwig

  • Meletios A. Dimopoulos

  • Martin Kaiser

  • Roman Hajek

  • Joseph Mikhael

  • Kim Cocks

  • Sumeet Panjabi

Medical Centers

  • Universitts-Frauenklinik Tubingen, Tubingen, Germany

  • Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria

  • National and Kapodistrian University of Athens, Athens, Greece

  • Institute for Cancer Research, London, United Kingdom

  • University Hospital, Ostrava, Czech Republic

  • International Myeloma Foundation, North Hollywood, CA

  • KCStats Consultancy, Leeds, United Kingdom

  • Amgen Inc, South San Francisco, CA

Locations

  • Czech Republic

  • Greece

  • Austria

  • Germany

  • United Kingdom

  • United States

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • carfilzomib Intravenous

  • Bortezomib

  • ZoMaxx

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01568866

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved